Trial Profile
Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2015
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 13 Dec 2015 New trial record